NCT05925738 is a clinical trial of PET/CT-based Deep Learning Signature in Non-small Cell Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT05925738?

NCT05925738 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT05925738?

Interventions in NCT05925738: PET/CT-based Deep Learning Signature.

What condition does NCT05925738 study?

NCT05925738 studies Non-small Cell Lung Cancer, Spread Through Air Space, Visceral Pleural Invasion, Lymphovascular Invasion.

Is NCT05925738 still recruiting?

NCT05925738 is currently status unknown. Last updated 29 June 2023.

Last reviewed 2023-06-29 · How we verify

NCT05925738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer

Status unknown Last updated 29 June 2023

What this trial tests

trial testing PET/CT-based Deep Learning Signature in Non-small Cell Lung Cancer in 1,500 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
31 October 2023

31 October 2023

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	1 May 2023
Primary completion	31 October 2023
Estimated completion	31 October 2023
Sites	3 locations across China

Drugs / interventions tested

PET/CT-based Deep Learning Signature

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Spread Through Air Space — all drugs for Spread Through Air Space →
Visceral Pleural Invasion — all drugs for Visceral Pleural Invasion →
Lymphovascular Invasion — all drugs for Lymphovascular Invasion →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 20 to 75, any sex, with Non-small Cell Lung Cancer or Spread Through Air Space. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting aggressive histological pattern in resected non-small cell lung cancer based on a multicenter prospective cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET/CT-based Deep Learning Signature

Trials testing the same drug.

NCT05425134 — Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer · unknown

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05925738 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 29 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05925738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing